

Juan Lantero Rodriguez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5949498/publications.pdf>

Version: 2024-02-01

33
papers

3,059
citations

279487

23
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

2025
citing authors

#	ARTICLE	IF	CITATIONS
1	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. <i>Brain</i> , 2022, 145, 2834-2848.	3.7	20
2	Plasma p-tau231, p-tau181, ^{PET} Biomarkers, and Cognitive Change in Older Adults. <i>Annals of Neurology</i> , 2022, 91, 548-560.	2.8	42
3	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	2.7	65
4	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. <i>Alzheimer's and Dementia</i> , 2022, 18, 2614-2626.	0.4	22
5	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. <i>Acta Neuropathologica</i> , 2022, 143, 487-503.	3.9	89
6	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535.	5.3	73
7	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	4.9	99
8	Population-based blood screening for pre-clinical Alzheimer's disease: a British birth cohort at age 70. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A91.2-A91.	0.9	0
9	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976.	4.1	76
10	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.4	81
11	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	3.7	124
12	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	4.1	186
13	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17.	3.0	35
14	Neuroigin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. <i>Acta Neuropathologica Communications</i> , 2021, 9, 19.	2.4	17
15	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	3.9	285
16	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	3.0	34
17	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	1.5	15
18	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146

#	ARTICLE	IF	CITATIONS
19	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	2.7	54
20	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, .	1.5	50
21	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
22	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.4	174
23	OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449.	3.7	54
24	p-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098.	3.3	30
25	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. <i>Communications Biology</i> , 2021, 4, 1265.	2.0	4
26	Distinctive effect of biological sex in AD-related CSF and plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
27	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278.	3.9	209
28	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1129-1141.	1.2	55
29	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202
30	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539.	0.4	2
31	Diagnostic and prognostic value of serum NfL and p-Tau ₁₈₁ in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 960-967.	0.9	93
32	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
33	AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. <i>Diabetologia</i> , 2017, 60, 729-739.	2.9	20